At the time of writing, Xenon Pharmaceuticals Inc [XENE] stock is trading at $32.26, up 0.31%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The XENE shares have gain 5.91% over the last week, with a monthly amount drifted -10.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xenon Pharmaceuticals Inc [NASDAQ: XENE] stock has seen the most recent analyst activity on May 07, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $55. Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $67. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $53 on October 01, 2024. Citigroup initiated its recommendation with a Buy and recommended $62 as its price target on January 04, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on December 08, 2023, and assigned it a price target of $63.
For the past year, the stock price of Xenon Pharmaceuticals Inc fluctuated between $26.74 and $46.00. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $32.26 at the most recent close of the market. An investor can expect a potential return of 30.19% based on the average XENE price forecast.
Analyzing the XENE fundamentals
Gross Profit Margin for this corporation currently stands at -0.09% with Operating Profit Margin at -39.07%, Pretax Profit Margin comes in at -34.07%, and Net Profit Margin reading is -33.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.32 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.74 points at the first support level, and at 31.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.95, and for the 2nd resistance point, it is at 33.64.
Ratios To Look Out For
It is important to note that Xenon Pharmaceuticals Inc [NASDAQ:XENE] has a current ratio of 17.66. Also, the Quick Ratio is 17.66, while the Cash Ratio stands at 13.45. Considering the valuation of this stock, the price to sales ratio is 330.06, the price to book ratio is 3.51.
Transactions by insiders
Recent insider trading involved GANNON STEVEN, Director, that happened on Jun 05 ’25 when 3.0 shares were sold. PRESIDENT & CEO, MORTIMER IAN completed a deal on Jan 24 ’25 to sell 22468.0 shares. Meanwhile, PRESIDENT & CEO MORTIMER IAN sold 16315.0 shares on Jan 27 ’25.
